Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Crescent Biopharma (CBIO) Research & Development (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Research & Development for 11 consecutive years, with $78.2 million as the latest value for Q4 2025.

  • Quarterly Research & Development changed N/A to $78.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $110.6 million through Dec 2025, changed N/A year-over-year, with the annual reading at $138.1 million for FY2025, 868.36% up from the prior year.
  • Research & Development for Q4 2025 was $78.2 million at Crescent Biopharma, up from $20.3 million in the prior quarter.
  • The five-year high for Research & Development was $78.2 million in Q4 2025, with the low at $14776.0 in Q1 2025.
  • Average Research & Development over 5 years is $11.7 million, with a median of $6.3 million recorded in 2024.
  • Peak annual rise in Research & Development hit 722.77% in 2025, while the deepest fall reached 99.75% in 2025.
  • Over 5 years, Research & Development stood at $12.9 million in 2021, then plummeted by 54.32% to $5.9 million in 2022, then fell by 10.23% to $5.3 million in 2023, then plummeted by 53.24% to $2.5 million in 2024, then soared by 3062.15% to $78.2 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $78.2 million, $20.3 million, and $12.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.